QuidelOrtho shares rise 14.02% premarket after reporting Q2 earnings with improved EBITDA margin and cost savings.

QuidelOrtho Corporation rose 14.02% in premarket trading, driven by positive financial results for the second quarter of 2025. The company reported total revenue of $614 million, with labs revenue growing 4% as reported and 5% in constant currency. Additionally, the company achieved $100 million in annualized cost savings and reiterated its full-year 2025 financial guidance.